|
Association Between Genetic Polymorphisms and Type 2 Asthma in Children
RECRUITINGSponsored by Guangzhou Institute of Respiratory Disease
Actively Recruiting
SponsorGuangzhou Institute of Respiratory Disease
Started2024-01-30
Est. completion2025-12-30
Eligibility
Age3 Years – 14 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06840717
Summary
To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.
Eligibility
Age: 3 Years – 14 YearsHealthy volunteers accepted
Inclusion Criteria: 1. All children with asthma diagnosis accord with the GINA in 2023 edition; 2. Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies; 3. In front of the hospital 2 weeks without antibiotics, systemic hormone medication history; 4. There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc. Exclusion Criteria: 1. Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission; 2. Children with primary immunodeficiency disease; 3. The children and their families failed to cooperate or refused the experimental observation.
Conditions4
AsthmaAsthma in ChildrenGenetic DiseaseInflammation
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorGuangzhou Institute of Respiratory Disease
Started2024-01-30
Est. completion2025-12-30
Eligibility
Age3 Years – 14 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06840717